Skip to main content

Atea Pharmaceuticals Appoints Polly Murphy, D.V.M, Ph.D., to the Board of Directors

Written by Customer Service on . Posted in Public Companies.

BOSTON, Sept. 14, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Polly Murphy, D.V.M., Ph.D., Chief Business Officer of UroGen Pharma, to its Board of Directors. Dr. Murphy is a seasoned pharmaceutical executive with a wide range of experience spanning research and development, strategy and operations.“We are thrilled to welcome Dr. Murphy to Atea’s Board of Directors as her expertise and leadership in clinical, business and commercial development will be invaluable as we continue to advance our pipeline of antiviral product candidates. Her insight and guidance will be particularly beneficial as we accelerate the development of AT-527 as an oral treatment for patients with COVID-19,” said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea Pharmaceuticals.“It is an honor to join Atea’s Board particularly at this time when there is such urgent need for safe and effective antiviral therapeutics.  I am looking forward to working closely with this dedicated team to advance development and commercialization of AT-527 and other product candidates which may transform clinical outcomes for patients with life threatening viral diseases,” commented Dr. Murphy. Prior to joining UroGen, Dr. Murphy held several senior leadership positions at Pfizer, including commercial development leadership in the Pfizer Oncology Business Unit and at Pfizer China where she was responsible for business and commercial development, as well as strategy and innovation for the company’s biopharmaceutical business in China. Earlier, she held senior positions at The Scripps Research Institute and The Salk Institute for Biological Studies.Dr. Murphy earned a D.V.M. and Ph.D. in Veterinary Pathology from Iowa State University and an M.B.A. from Nova Southeastern University.About Atea PharmaceuticalsAtea Pharmaceuticals is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Our lead programs are focused on the development of orally-administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. Our medicinal chemistry, virology, and pharmacology expertise, bolstered by our collective experience in drug development, enables us to pioneer new advancements in antiviral science. Leveraging the power of our purine nucleotide prodrug platform, our goal is to rapidly advance novel drug candidates with optimal therapeutic profiles for RNA virus targets. Founded by our Chairman and Chief Executive Officer, Jean-Pierre Sommadossi, PhD, Atea began operations in 2014 and is headquartered in Boston, MA. For more information about Atea and our pipeline of product candidates please visit our company website at ateapharma.com.  ContactsInvestors:
Will O’Connor
Stern Investor Relations 
will.oconnor@sternir.comMedia:
Carol Guaccero 
301-606-4722
contactus@ateapharma.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.